BALTIMORE, MD – (April 12, 2017) Three grassroots foundations founded by the families of young boys diagnosed with Duchenne muscular dystrophy (DMD) have jointly awarded a $100,000 grant to Kennedy Krieger Institute's Center for Genetic Muscle Disorders for research into novel drug therapies. The funding from Ryan's Quest, of New Jersey, along with Michael's Cause and Pietro's Fight, both of New York, will enable the scientific team to study existing drugs that have shown ea

SEATTLE, Feb. 24 2017 /PRNewswire/ -- DMD Therapeutics, Inc., a start-up biotech company, is developing proprietary therapeutics for Duchenne muscular dystrophy (DMD), an orphan disease associated with serious morbidity and early mortality that has a major unmet need. The Company's first drug candidate, DMD-813, has been shown to reduce damage and inflammation in muscle leading to markedly increased muscle strength in the standard mouse model of DMD (mdx mice). Further studie

HAMILTON, N.J., March 24, 2016 /PRNewswire-iReach/ -- Ryan's Quest, a New Jersey based non-profit organization dedicated to finding treatments and a cure for Duchenne muscular dystrophy (DMD) is thrilled to announce the collaboration of five global Duchenne foundations to provide a $596,700 research grant to fund a promising Duchenne research project for Jerome Frenette Ph.D at The University of Laval in Quebec, Canada. Michael's Cause (USA), Pietro's Fight (USA), Save Our So